Loading
Labcorp's blood tests for leftover cancer: a whole-genome version for stage III colon cancer and a personalised-panel version for early breast and lung cancer.
Labcorp launched Plasma Detect in April 2024 for research use, as a tumour-informed whole-genome MRD test validated in early-stage colon cancer, and made it available for clinical use on 23 April 2025 in stage III colon cancer, initially through an early experience programme, with a stated limit of detection (LOD95) of 0.005%. On 13 January 2026 it made the whole-genome test, now Plasma Detect Genome, available nationwide for stage III colon cancer and added Plasma Detect ID, a whole-exome-guided personalised panel for stage I-III breast cancer and stage I-IIIA non-small cell lung cancer. Labcorp bought selected assets of Invitae on 5 August 2024, and Plasma Detect ID is listed in Invitae's test catalogue with the same 18-to-50-variant exome design as Invitae's Personalized Cancer Monitoring assay (Molecular Diagnosis & Therapy 2023). The tests have not been cleared or approved by the FDA.
Two tumour-informed designs. Plasma Detect Genome uses whole-genome sequencing of the tumour and does not need a bespoke panel to be manufactured for each patient. Plasma Detect ID uses exome sequencing of tumour and blood to design a patient-specific panel of 18 to 50 variants.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Labcorp Plasma Detect" OR ABSTRACT:"Labcorp Plasma Detect" OR TITLE:"Plasma Detect Genome" OR ABSTRACT:"Plasma Detect Genome" OR TITLE:"Plasma Detect ID" OR ABSTRACT:"Plasma Detect ID" OR TITLE:"Labcorp Plasma Detect ID MRD" OR ABSTRACT:"Labcorp Plasma Detect ID MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Labcorp Plasma Detect, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Haystack MRD, Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tag test.
Shares Tumour-informed versus tumour-naive ctDNA assays, ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/